^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    refametinib (BAY86-9766)

    i
    Company:
    AstraZeneca
    Drug class:
    MEK inhibitor, ERK2 inhibitor
    Related drugs:
    Apply
    Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC) (NCT01915589)
    Phase 2
    Bayer
    Completed
    Last update posted :
    04/08/2021
    Initiation :
    09/16/2013
    Primary completion :
    10/08/2014
    Completion :
    10/08/2014
    KRAS • NRAS
    |
    NRAS mutation • RAS mutation
    |
    refametinib (BAY86-9766)
    Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC) (NCT01915602)
    Phase 2
    Bayer
    Completed
    Last update posted :
    04/08/2021
    Initiation :
    09/27/2013
    Primary completion :
    07/29/2015
    Completion :
    02/08/2017
    KRAS • NRAS
    |
    NRAS mutation • RAS mutation
    |
    sorafenib • refametinib (BAY86-9766)